Recruiting
Early Phase 1

Momelotinib with Azacitidine

Sponsor:

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Code:

NCT07071155

Conditions

Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes

Myeloproliferative Overlap Neoplasms

Chronic Neutrophilic Leukemia

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Momelotinib

Azacitidine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-12. This information was provided to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins on 2026-03-27.